Entering the 2024 season, Just Baseball ranked J.P. Crawford of the Seattle Mariners as the ninth-best shortstop in the ...
The position does not call for an attorney, but that is what the magisterial district might just get, since this recent ...
(NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced two ...
The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...
Leerink Partners analyst Marc Goodman has maintained their bullish stance on MNMD stock, giving a Buy rating yesterday.Invest with Confidence: ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few years now.
Those who own JNJ stock may stay invested for some time as the company looks optimistic about a better performance in 2025.
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Failed to fetch dynamically imported module: https://sg.finance.yahoo.com/assets/_app/immutable/nodes/100.C0JpamNs.js ...
Hosted on MSN12d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback